Translational and cross-species studies of the impact of cannabis use and HIV on mitochondrial homeostasis in brain macrophages
Active Grant Awarded Last action
- Award ID
- R01DA065256
- Recipient
-
University Of California, San Diego UEI UYTTZT6G9DT1
- Awarding agency
-
National Institute on Drug Abuse
National Institutes of Health, Department of Health and Human Services
- Obligated
- $1,500,942
Award facts
- Assistance listing
- 93.279 Drug Use and Addiction Research Programs
- Completion date 10% complete
- Place of performance
- La Jolla, CA 92093, USA
Award details come from USAspending.gov.
About this award
The Department of Health and Human Services, National Institutes of Health, National Institute on Drug Abuse awarded the University of California, San Diego a $1.500942 million grant on May 22, 2026, under Assistance Listing 93.279, Drug Use and Addiction Research Programs (Grant R01DA065256). The award funds a translational study testing whether cannabis use alters TREM2-mediated brain mitochondrial homeostasis in people with HIV aged over 50. The work combines a clinical observational study, which measures plasma and cerebrospinal fluid biomarkers across cannabis use ranging from naive to daily, with preclinical work: personalized ex vivo and in vitro modeling of mitochondrial toxicity in brain macrophages and neurons, and mouse models of HIV-induced neurotoxicity (ECO-HIV) and age-related neuropathogenesis (TREM2*R47H). The project tests the hypothesis that moderate use is beneficial while chronic daily use is detrimental. The ultimate completion date is April 30, 2031, and the place of performance is La Jolla, CA 92093.
Subaward R01DA065256-708151, dated July 15, 2026, passes part of the work to Veterans Medical Research Foundation of San Diego. The subrecipient will recruit veterans, screen them against study criteria through interviews, rating scales, and biomedical testing, and exclude candidates for MRI contraindications. It will collect blood samples to measure free radioligand available to enter the brain, and saliva samples for TSPO genotyping, which the laboratory of Brinda Rana will analyze to exclude low-affinity binders. It will refer eligible participants to the UCSD portion, which includes laboratory testing, PET/CT scanning with the radiotracer 18F-FEPPA, and structural MRI. Dr. Brody and research assistants will analyze the PET/CT and MRI data.
Description
- Abstract
- People with HIV (PWH) remain vulnerable to central nervous system complications (e.g., neurocognitive impairment) despite antiretroviral therapy (art) that suppresses viral replication. While many etiologies of these complications exist, mitochondrial dysfunction and inflammation are consistently implicated yet seldom studied simultaneously. PWH also use cannabis more frequently than the general population and recent evidence by our group and others indicates that cannabis may protect PWH from mitochondrial damage by improving metabolic homeostasis and reducing inflammation through triggering receptor expressed on myeloid cells (TREM) 2. Moreover, this mechanism may be more important as PWH age, with the average age of PWH currently being >55. This proposed multidisciplinary, translational project will combine a clinical observational study with cellular and in vivo preclinical models to determine the effects of cannabis use on TREM2-mnediated changes in mitochondrial function in the brain in PWH. The preclinical models will include a) personalized EX vivo/in vitro modeling of mitochondrial toxicity in brain macrophages and neurons, and B) a mouse model for HIV-induced neurotoxicity (ECO-HIV) and age-related neuropathogenesis (TREM2*R47H). Using this multilevel approach, we will test the hypothesis that cannabis effects on TREM2-mediated changes in brain mitochondrial homeostasis vary based on patterns of use: moderate use will be associated with beneficial effects, due to the TREM2 promoting and anti-inflammatory properties of cannabis, but chronic daily use will have detrimental effects. In a cohort of aged (>50 years old) PWH across a range of cannabis use from naïve to daily users, we will measure in plasma and cerebrospinal fluid (CSF) a panel of biomarkers that reflect the mitochondrial homeostasis, TREM2 function, and inflammation. These readouts will be correlated with neurocognitive assessments and pet imaging for tspo, a marker of neuroinflammation associated with mitochondrial function (aim 1). We will model brain macrophages using personalized EX vivo cultures of monocyte derived microglia collected from aim 1 study participants and culture these cells with neurons to identify mechanisms of mitochondrial dysfunction (aim 2). Using a cross-species approach, we will investigate how different precise doses of cannabinoids interact with HIV and TREM2 variants to affect mitochondrial homeostasis in wild-type and TREM2*R47H mice infected with ecohiv (aim 3). This highly innovative, multidisciplinary research proposal is very likely to generate impactful translational knowledge regarding mechanisms of pathogenesis and guide future therapeutic interventions. With our combined clinical and pre-clinical expertise in HIV infection, substance abuse, imaging, and mitochondrial homeostasis, we are uniquely suited to perform the proposed research.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Amendment | $0 | |
| Original award | $1,500,942 |
Subawards
| Subrecipient | Amount | Awarded |
|---|---|---|
| Veterans Medical Research Foundation Of San Diego | $130,917 |
Quick answers
Who received award R01DA065256?
R01DA065256 was awarded to University Of California, San Diego by National Institute on Drug Abuse (National Institutes of Health) on May 22, 2026.
How much is award R01DA065256 worth?
$1,500,942 has been obligated on R01DA065256.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award